The effect of continuous versus pericycle antiretroviral therapy on IL-2 responsiveness

Journal of Interferon and Cytokine Research

Volumn 28, Issue 7, 2008, Pages 455-461

  Healey, Letha M ^a   Hahn, Barbara K ^a   Rehm, Catherine A ^b   Adelsberger, Joseph ^c   Qin, Jing ^b   Follmann, Dean A ^b   Tavel, Jorge ^b   Kovacs, Joseph A ^a   Sereti, Irini ^b   Davey Jr , Richard T ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL ARTICLE; DRUG INTERMITTENT THERAPY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV-1; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 47249085552     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0120     Document Type: Article

References (16)

1. Allende MC, Lane HC. 2001. Cytokine-based therapies for HIV infection. AIDS 15(Suppl 5):S183-S191.
2. Angus B, ESPRIT, STALWART, SILCAAT Trial Steering Committees. 2006. Interleukin 2 treatment in HIV-1 infection. Lancet 367:1054-1055.
3. Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, Masur H, Follmann DA, Lane HC, Davey RT. 2004. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 103(9):3282-3286.
4. Havlir DV, Currier JS. 2006. Complications of HIV disease and antiretroviral therapy. Top HIV Med 14:27-35.
5. 3 after treatment interruption following antiretroviral therapy +/- interleukin 2: Results of ACTG A5102. J Acquir Immune Defic Syndr 42:140-148.
6. Keh CE, Shen JM, Hahn B, Hallahan CW, Rehm CA, Thaker V, Wynne SM, Davey RT, Lane HC, Sereti I. 2006. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. AIDS 20:361-369.
7. + T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 115:2139-2148.
8. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC. 1996. Controlled trial of interleukin-2 infusions in patients infected with the Human Immunodeficiency Virus. NEJM 335(18):1350-1356.
9. Laird NM, Ware JH. 1982. Random-effects models for longitudinal data. Biometrics 38:963-974.
10. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux A, Michon C, Oksenhendler E, Weiss L, Gastaut J, Goujard C, Rouziouz C, Maral J, Delfraissy J, Emilie D, Aboulker J. 2003. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial. AIDS 17:343-351.
11. Lifson AR, Rhame FS, Belloso WH, Dragsted UB, El-Sadr WM, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Pett SL, Davey RT Jr. 2006. Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. HIV Clin Trials 7:125-141.
12. Lunceford JK, Davidian M. 2004. Stratification and weighting via the propensity score in estimation of causal treatment effects: A comparative study. Stat Med 23:2937-2960.
13. Pett SL, Emery S. 2001. Immunomodulators as adjunctive therapy for HIV-1 infection. J Clin Virol 22:289-295.
14. + T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104(3):775-780.
15. Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, Berg SC, Metcalf JA, Hahn BK, Shen JM, Powers A, Davey RT, Kovacs JA, Shevach EM, Lane HC. 2005. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 115:1839-1847.
16. Youle M, Emery S, Fisher M, Nelson M, Fosdick L, Janossy G, Loveday C, Sullivan A, Herzmann C, Wand H, Davey RT, Johnson MA, Tavel JA, Lane HC. 2006. A randomized trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: The UK-Vanguard Study. PLOS Clin Trials e3.